Cytek BioSciences opened lower at $5.68, compared with its previous close of $5.76. In the last trading session, the stock traded between $5.45 and $5.69. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Cytek BioSciences is now worth
$ 24.25
Resulting in a loss of
$ 75.75 (75.75%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
$-0.25 (-4.25%)
Day High
$5.69
Day Low
$5.45
Day Open
$5.68
Prev Close
$5.76
Volume
6,27,108
1W Return
-6.11%
1M Return
3.96%
3M Return
15.98%
6M Return
33.86%
1Y Return
15.14%
Market Cap ($ Mn)
721
PE Ratio
-
PB Ratio
1.89
PEG Ratio
-
ROE
-17.76%
ROCE
-7.63%
EPS (TTM)
$-0.05
1 Week
-6.11%
1 Month
3.96%
3 Months
15.98%
6 Months
33.86%
9 Months
26.49%
Cytek Biosciences Q3FY26 Results: Revenue up 2% to $53.2 million
Revenue grew 2% YoY to $53.2 million, led by 12% growth in the U.S. Gross margin expanded 600 bps to 59% due to manufacturing shifts to Singapore. High-end instrument placements grew 23%, driving an 11% rise in related revenue. Net loss widened to $6.1 million due to lower tax benefits despite improved operations. Full-year revenue guidance maintained at midpoint of $208-$211 million.
8 days agoCytek Biosciences to report Q3FY26 results on November 4
Cytek Biosciences will report Q3 2026 financial results on November 4, 2026. Management conference call scheduled for 4:30 pm Eastern Time on the same day. Live audio webcast available via the company's investor relations website. Products primarily for research use, with limited clinical exceptions in China and EU.
22 days agoCytek Biosciences to showcase spectral cytometry at ESCCA and ICCS
Cytek Biosciences will exhibit at ESCCA 2026 in Salzburg and ICCS 2026 in Miami. Company highlights Full Spectrum Profiling technology for MRD monitoring and diagnostics. Over 4,200 peer-reviewed publications cite use of Cytek's FSP systems. CEO Wenbin Jiang emphasizes focus on clinical workflow efficiency and standardization.
2mo agoCytek wins three patent claims but faces $56m award
Jury finds in favor of Cytek on three of four patent claims. Single remaining claim results in $56 million damages award. Award includes $20 million lost profits and $36 million royalties. Products remain available; no operational changes required.
2mo agoCytek Biosciences Raises FY26 Sales Guidance to $207M-$212M
Cytek Biosciences raised its FY2026 sales guidance to $207.000 million-$212.000 million from $205.000 million-$212.000 million. The revised outlook beats the $208.767 million analyst estimate, reflecting improved business confidence.
3mo agoCytek Biosciences to report Q2 2026 results on August 5
Cytek Biosciences will release its Q2 2026 financial results on August 5, 2026, followed by a conference call to discuss performance and outlook. The webcast will be available on the company's investor website.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in Cytek BioSciences is now worth
$ 24.25
Resulting in a loss of
$ 75.75 (75.75%)
Note: Past profits do not guarantee future returns.
